GlassScriptPhysician profile
Tony A Freeman
NPI 1285615278
$15,285.74
in general payments reported to CMS, 2019-2025
50 companies · $2,037 in 2025
The $2,037 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,856 · 2020: $2,364 · 2021: $2,773 · 2022: $2,170 · 2023: $2,105 · 2024: $1,980 · 2025: $2,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,122.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,489.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,182.83 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $1,149.30 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,144.65 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,003.87 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $785.74 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $728.19 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $572.74 | 2019-2023 | Xarelto |
| Abbvie INC. | $565.62 | 2019-2025 | |
| Gilead Sciences, INC. | $502.15 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $459.24 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.66 | 2019-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $343.70 | 2021-2025 | |
| Astellas Pharma US INC | $258.89 | 2019-2025 | Veozah, Myrbetriq |
| Aimmune Therapeutics, INC. | $252.93 | 2024-2025 | Zenpep |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.